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Short report Bovine ISG15: an antiviral and inducible protein in 
BIV infected fetal bovine lung cells
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Abstract
Bovine ISG15 (bISG15) is an interferon inducible ubiquitin-like protein that is responsible for the establishment of early 
pregnancy in ruminant, understanding the properties of bISG15 capable of being inducible in fetal bovine lung (FBL) 
cells upon infection of bovine immunodeficiency virus (BIV) is of significant importance. In this study, we investigated 
the expression of bISG15 in poly I:C treated FBL cells. The increased expression of bISG15 was observed, and the 
inhibition of BIV replication was also detected in FBL cells. Elimination of bISG15 expression by small interfering RNA 
reversed the bISG15 mediated inhibition of BIV replication. These findings demonstrate that bISG15 plays an important 
role in inhibition of the BIV replication in FBL cells. Furthermore, real-time PCR and western blot assay revealed that 
bISG15's expression can also be induced in BIV infected FBL cells. Taken together, bISG15 is an antiviral and inducible 
protein in BIV infected FBL cells.
Finding
Type I IFNs' binding to cell type specific receptors can
induce the synthesis of a plethora of proteins [1], many of
which play crucial roles in the antiviral response [2].
ISG15 was one of the most strongly induced proteins.
Thirty years past since ISG15 was first found [3], whereas
its antiviral function was reported recently [4]. ISG15, a
15-kDa ubiquitin-like protein, can be covalently conju-
gated to target proteins for post-translational modifica-
tion through a series of steps similar to ubiquitin
modification [5]. ISG15 and its conjugation modification
play roles in processes including regulation of IFN signal-
ing, innate immunity, anti-viral infections, pregnancy,
and carcinogenesis [4]. Interestingly, ISG15 and enzymes
involved in ISG15 modification are interferon inducible
[1,3,6-8]. This indicates ISG15 and its conjugation play
important roles in innate immunity and antiviral
response to infection. Mice deficient of ISG15 have been
shown to be more susceptible to influenza, herpes, and
Sindbis viruses' infection [9]. It has been reported that
ISG15 can inhibit the release of human immunodefi-
ciency virus type 1 (HIV-1) virions by disrupting the
interaction of the Gag L domain with Tsg101 [10], and
ISG15 can also repress the replication of Ebola virus by
inhibiting the release of virions [11]. Unlike ubiquitin or
other ubiquitin-like molecules, cross-species' conserva-
tion of ISG15 is low [4]. Therefore, it is necessary and
intriguing to elucidate the antiviral functions of ISG15 in
wide variety of species.
Bovine ISG15 (bISG15) has 70% homology amino acid
sequence to human ISG15 [12]. The studies about
bISG15 are mainly focused on its role in reproductive
biology. The expression of bISG15 is up-regulated at
endometrium in response to conceptus-secreted IFN-τ
during early pregnancy [13]. The relation between
bISG15 and innate immune response has also been
noticed. The expression of bISG15 in maternal blood is
increased in cows infected with acute non-cytopathic
bovine viral diarrhea virus (BVDV) [14]. However, the
reports about property of the bISG15 with antiviral func-
tion are scarce up to date. Recently, we have found that
expression of bISG15 can be induced in fetal bovine lung
(FBL) cells after treated with poly I:C or lipopolysaccaride
(LPS) [15]. FBL cells were chosen to be as a target type of
cells here, since our lab found that FBL cells could be
infected by viruses which are capable of infecting cattle,
such as BVDV, bovine foamy virus (BFV), and bovine
immunodeficiency virus (BIV). BIV can infect FBL cells
in vitro, and induce syncytia formation in FBL cells.
Moreover, BIV DNA can also be detected in bovine lung
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tissues [16]. BIV, which has a similar genome to HIV-1, is
associated with chronic inflammatory diseases in
infected cows [17]. Considering the similarity between
BIV and HIV-1, BIV may contribute as alternative animal
virus model for certain aspects of HIV research. It has
been reported that ISG15 can inhibit the replication of
HIV [10]. We previously demonstrated that bISG15 can
be induced robustly in poly I:C treated FBL cells [15].
Here, we further try to address whether the replication of
BIV can be repressed in FBL cells treated with poly I:C
and to address extensively whether the expression of
bISG15 is changed in FBL cells infected with BIV.
In this study, FBL cells were isolated from fetal bovine
lung issues. The primary FBL cells isolated from the lung
issues of fetal calf were called passage"1". When FBL cells
proliferated and separated, they were called passage "2"
and so on. All the FBL cells used in the experiment were
the passages between 10 and 20. BIV indicator cell line,
designated as BIVL, has an integrated reporter plasmid
which has a firefly luciferase reporter protein gene down-
stream of BIV LTR promoter [18]. FBL cells and BIVL
cells were maintained in Dulbecco's Modified Eagle
Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 50 IU/ml penicillin, 50 μg/ml streptomycin
in 5% CO2 at 37°C. Due to fail of obtaining cell free BIV, a
BIV strain R29 was used here. The BIV R29 strain was
maintained in FBL cells. All the BIV used in the experi-
ment were the FBL cells infected BIV. Poly I:C (purchased
from Sigma-Aldrich) was dissolved in PBS at a concentra-
tion of 2.5 mg/ml. BIVL cells were plated at a density of 4
× 104 per well in 12-well plates to indicate BIV infection
efficiency. BIVL cells co-cultured with BIV infected/
uninfected FBL cells at equal cell number. After 12 hours,
all cells were assessed by luciferase assays (Promega
luciferase assay kit) to indicate the replication efficiency
of BIV in FBL cells [18]. Synthetic siRNA of bISG15
(bISG15siRNA) and negative control siRNA (scrambled
siRNA) (purchased from GenePharma) were used as
annealed oligonucleotide and was resuspended in RNase-
free H2O, respectively. The sense sequence of scrambled
siRNA is 5'-UUC UCC GAA CGU GUC ACG UTT-3',
the anti-sense sequence of scrambled siRNA is 5'-ACG
UGA CAC GUU CGG AGA ATT-3'; and the sense
sequence of bISG15siRNA is 5'-CAC CGU GUU CAU
GAA UCU ATT-3', the anit-sense sequence of
bISG15siRNA is 5'-UAG AUU CAU GAA CAC GGU
GTT-3'. To validate the suppressing effect of bISG15,
bISG15siRNA or scrambled siRNA (100 Nmol/hole) was
transfected to FBL cells with Lipofectamine 2000 (Invit-
rogen), respectively. Realtime PCR and Western blot
assay of bISG15 were performed as previously described
[15]. Briefly, total RNA from cells was isolated with TRI-
zol reagent (Invitrogen) following the manufactures's
instructions, and then the extracted RNA was reverse
transcribed into cDNA by reverse transcriptase (Pro-
mega). Real time PCR was performed using an IQ5 Mul-
ticolor Real-time PCR detection system (Bio-Rad) and
fluorescent EVAGreen nucleic acid stain (Biotium). Prim-
ers used to quantify bISG15's cDNA were bISG15-F (5'-
GTG GTG CAG AAC TGC ATC TC-3') and bISG15-R
(5'-GCC AGA ACT GGT CTG CTT GT-3'). GAPDH
cDNA served as endogenous control, GAPDH was ampli-
fied using the primers bGAPDH-F (5'-AAC GGC ACA
GTC AAG GCA GA-3') and bGAPDH-R (5'-TCG GCA
GAA GGT GCA GAG AT-3'). The level of bISG15 tran-
scription was normalized to GAPDH using the 2-ΔΔCt
method. The polyclonal murine bISG15 antibody used in
western blot assays was obtained in our lab. Western blot
detection was performed using the chemiluminescence
detection regent (Santa Cruz). T o ensure equal protein
loading, anti-β-actin antibody (Santa Cruz) was used to
detect β-actin expression in cells.
In order to test the capacity indicative of BIV infection,
different numbers of BIV-infected FBL cells were added
to BIVL cells. To make the number of all FBL cells at
equal level of 200 × 102, naive FBL cells free of BIV infec-
tion were added. Infected/naive FBL cells co-cultured
with BIVL for 12 hours, and then the cells were taken
luciferase assays. Naive FBL cells were added to the BIVL
as negative control. As shown in Figure 1.a, the level of
induced luciferase activity is in a dose dependent manner,
which means the increased expressing level of luciferase
activity is correlated with the increased numbers of BIV-
infected FBL cells. It illustrated that BIVL reliably reveals
BIV infection allowing infected cells to be tracked with
high sensitivity. Thus, BIVL can act as an indicator cell
line in this experiment. In the later experiments, the
number of FBL cells infected BIV added in BIVL cells is
about 100 × 102. In order to detect the effect of poly I:C
treatment on BIV in FBL cells, the BIV infected FBL cells
were divided into four groups as follows: "NC (negative
control)" group, "BIV" group, "BIV + poly I:C" group and
"poly I:C" group. Poly I:C was added in "BIV + poly I:C"
group and "poly I:C" group, respectively, to reach a final
concentration of 50 μg/ml at 2 hours before the BIV
infection. BIV infection was performed in FBL cells in
"BIV" group and "BIV+poly I:C" group, while mock-infec-
tion was performed in FBL cells in "NC" group and "poly
I:C" group, respectively. After being infected for 12 hours,
these cells were added to BIVL to perform luciferase
activity assay. All the experiments were carried out more
than 3 times. The luciferase activity of "NC" group was
regarded as 1, and the relative luciferase activity folds of
other groups were calculated divided by the activity of
"NC" group. As shown in Figure 1.b, comparing with the
"BIV" group, the replication of BIV was inhibited in FBL
treated with poly I:C, whereas, no change of BIV replica-
tion was observed in the "NC" group nor did in the "polyLiu et al. Virology Journal 2010, 7:134
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I:C" group. It suggested that the treatment of poly I:C in
F B L  c e l l s  h a d  n o  e f f e c t  o n  t h e  b a c k g r o u n d  a c t i v i t y  o f
BIVL.
Poly I:C, which is the synthetic double-stranded RNA
(dsRNA), can robustly induce synthesis of IFN or ISGs
directly without the participation of IFNs [19]. TLR3,
cytoplasmic RNA helicases RIG-1 and Mda-5, can recog-
nize dsRNA and initiate the IRF-3 or IRF-7 signalling cas-
cades, which sequentially induce transcriptions of some
ISGs [20]. Poly I:C induces a number of ISGs with antivi-
ral functions, and the antiviral ISGs contribute to the
inhibition of BIV replication. To determine the critical
role of bISG15 in poly I:C mediated inhibition of BIV, we
designed the small interfering RNA (siRNA) of bISG15
gene. To demonstrate the siRNA can repress the expres-
sion bISG15 successfully, 239T cells were transfected
with bISG15-EGFP expression plasmid only or co-trans-
fected with bISG15-EGFP expression plasmid and the
siRNA (scrambled siRNA or bISG15 siRNA). As shown
in Figure 2.a, the siRNA of bISG15 can repress the
expression of bISG15-EGFP specifically, and the scram-
bled siRNA can not effect the expression of bISG15-
EGFP. In order to confirm our results, FBL cells infected
with BIV served as a positive control, and untreated cells
served as a negative control. FBL cells were transfected
with bISG15siRNA or scrambled siRNA, followed by
treatment with poly I:C. for 2 hours, then FBL cells were
infected with BIV. After 12 hours post-infection, cells
were added to BIVL to perform luciferase activity assay.
The luciferase activity of negative control group was
regarded as 1, relative luciferase activity folds of other
groups were calculated as divided by the activity of the
negative control group. As shown in Figure 2.b, these
results suggested bISG15 siRNA reverse the inhibition of
BIV in poly I:C treated FBL cells, whereas scrambled
siRNA did not present such a role of reversion. Taken
together, it suggested that bISG15 played a role in poly
I:C-induced inhibition of BIV in FBL cells.
We demonstrated that bISG15 played a role in inhibit-
ing the replication of BIV in FBL cells. In addition, we
found the expression of bISG15 in naive FBL cells is very
low, it is intriguing to address the question, and how the
expression of bISG15 change in FBL cells after being
infected with BIV. In order to validate whether the level
of the bISG15 was increased in FBL cells with infection of
BIV, bISG15 was detected by western blot using the anti-
serum against bISG15. FBL cells treated with poly I:C or
LPS served as a positive control. FBL cells treated with
PBS or mock-infected with naive FBL cells were used as
negative controls. After 6 h, cells were collected to per-
form western blot. It was found that free bISG15 was
d e t e c t e d  i n  t r e a t e d  o r  B I V  i n f e c t e d  F B L  c e l l s ,  e v e n
though the expression level of bISG15 was not strong. In
contrast, bISG15 positive bands were not observed in
untreated or mock-infected FBL cells, as shown in Figure
3.b. We found that the level of bISG15 was increased in
FBL cells treated with poly I:C/LPS or FBL cells infected
with BIV. In order to detect the transcription of bISG15
during viral infection, total RNA from FBL cells infected
w i t h  B I V  w e r e  a n a l y z e d  b y  r e a l - t i m e  P C R .  F B L  c e l l s
Figure 1 The replication of BIV was repressed in poly I:C treated 
FBL cells. a. BIV infection in FBL cells was measured quantitatively by 
BIV indicator cell line - BIVL cells. The × axis indicated the numbers of 
BIV infected cells; and the y axis indicated the relative luciferase activity 
folds. BIVL cells were plated at a density of 4 × 104 per well in 12-well 
plates. 1, 5, 10, 20, 50, 100 × 102 FBL cells were infected with BIV respec-
tively, and normalized to the equal number (200 × 102) by adding na-
ive FBL cells. The luciferase activity of adding only naive FBL cells was 
regarded as 1, and the relative luciferase activity folds of other groups 
were calculated. The relative folds were 1, 1.24, 2.73, 4.27, 7.23, 17.20, 
and 33.58. b. The replication of BIV in FBL cells indicated by relative lu-
ciferase activity in four experimental groups. The × axis indicates the 
four different experimental groups including the "NC" group (negative 
control), "BIV" group, "BIV + poly I:C" group, and "poly I:C" group; the y 
axis indicates the relative luciferase activity folds. The bars showed the 
relative luciferase activity folds of four groups respectively. All the ex-
periments were carried out more than 3 times, the error bars are stan-
dard deviation (SD) from triplicate results.Liu et al. Virology Journal 2010, 7:134
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infected with BIV were collected at 3 h, 6 h, and 18 h post
infection and were carried out real-time PCR. As the neg-
ative control, FBL cells were mock-infected with an equal
number of uninfected FBL cells. The bISG15's transcrip-
tion was induced in FBL cells with infection of BIV as
shown in Figure 3.a. These experiments confirmed that
the expression of bISG15 is induced in FBL cells infected
with BIV.
This study demonstrates that bISG15 is an antiviral and
inducible protein in BIV infected fetal bovine lung cells.
BIV infection can induce the expression of bISG15 in FBL
cells, but it is still unclear that the detail involved in this
process. It was shown in Figure 3.a, the induction of
bISG15 in FBL cells infected with BIV was decreased at 3
hours post-infection, while FBL cells infected with BIV at
18 hours post-infection were still alive, not dead obvi-
ously. To infect the naive FBL cells, we added the BIV
infected FBL cells to naive FBL cells. All cells involved in
this experiment were exclusively FBL cells not other cells.
FBL cells infected with BIV may activate some signal
pathways like interferon, NF-κB signal pathway and so
on. These signal pathways may induce the expression of
bISG15 directly or some cytokines such as Type I inter-
feron. These cytokines then induce the expression of
bISG15. It indicates that the induction of bISG15's
expression in FBL cells by BIV infection may be related to
several viral and cellular events via unknown mechanism.
Our results suggested that bISG15 played a role in poly
I:C-induced inhibition of BIV in FBL cells. The function
of bISG15 repressing the replication of BIV in FBL cells
demonstrates that bISG15 is a key mediator induced in
Figure 2 bISG15 plays a role in poly I:C induced-inhibition of BIV in FBL cells. a. The fluorescence microscopic image of 239T cells transfected 
with bISG15-EGFP expression plasmid, co-transfected with bISG15-EGFP expression plasmid and the scrambled siRNA, co-transfected with bISG15-
EGFP expression plasmid and the bISG15siRNA respectively. b. bISG15siRNA can reverse the inhibition of BIV replication in FBL cells treated with poly 
I:C. The × axis indicates the four different experimental groups including the "BIV+ poly I:C+ scrambled siRNA" group, "BIV+ poly I:C + bISG15siRNA" 
group, "BIV + poly I:C" group and "BIV" group; the y axis indicates the relative luciferase activity folds. The bars show the relative luciferase activity of 
four groups, respectively. All the experiments were carried out more than 3 times, and the error bars are the standard deviation.Liu et al. Virology Journal 2010, 7:134
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FBL cells inhibition of BIV replication and also reveals
the antiviral function of ISG15 in other species.
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Figure 3 The expression of bISG15 is induced in FBL cells infected 
with BIV. a. The transcription of bISG15 increases in FBL cells infected 
with BIV. The × axis indicates experimental groups including FBL cells 
mock-infected, FBL cells infected with BIV at post-infection of 3 h, 6 h, 
and 18 h, respectively. The y axis indicates the relative folds of bISG15's 
mRNA level. b. bISG15 expression was detected in FBL cells treated 
with poly I:C or LPS and FBL cells infected BIV by western blot assay.